Clinical trialNCT01030783CompletedPhase 3Interventional

A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma

SponsorAVEO Pharmaceuticals, Inc.Enrollment517Advanced Renal Cell Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Robert J. Motzer, MD
Memorial Sloan Kettering Cancer Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

86 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Site 102
Sante Fe, Argentina

Bulgaria

Site 403
Plovdiv, Bulgaria
Site 400
Sofia, Bulgaria
Site 404
Sofia, Bulgaria
Site 401
Varna, Bulgaria
Site 402
Veliko Tarnovo, Bulgaria

Canada

Site 110
Montreal, Quebec, Canada

Chile

Site 121
La Reina, Santiago de Chile, Chile
Site 122
Santiago, Chile
Site 123
Temuco, Chile

Czechia

Site 411
Prague, Czechia

France

Site 130
Marseille, France
Site 133
Saint-Herblain, France

Hungary

Site 423
Budapest, Hungary
Site 421
Kaposvár, Hungary
Site 422
Pécs, Hungary
Site 424
Szombathely, Hungary

India

Site 157
Hyderabad, Andhra Pradesh, India
Site 190
Patna, Bihar, India
Site 156
Ahmedabad, Gujarat, India
Site 151
Nashik, Maharashtra, India
Site 153
Pune, Maharashtra, India
Site 159
Pune, Maharashtra, India
Site 155
Jaipur, Rajasthan, India
Site 191
Jaipur, Rajasthan, India
Site 152
Vellore, Tamil Nadu, India
Site 158
Lucknow, Uttar Pradesh, India
Site 150
Kolkata, West Bengal, India
Site 154
Delhi, India

Italy

Site 160
Arezzo, Italy
Site 161
Pavia, Italy
Site 162
Roma, Italy

Poland

Site 432
Bialystok, Poland
Site 434
Bydgoszcz, Poland
Site 431
Gdansk, Poland
Site 435
Olsztyn, Poland
Site 433
Poznan, Poland
Site 430
Warsaw, Poland
Site 436
Warsaw, Poland

Romania

Site 444
Brasov, Romania

46 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Sorafenib →Tivozanib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2009
Primary completion: 31 Jul 2012
Completion: 30 Jun 2013
Last update posted: 28 Oct 2019
Registered enrollment: 517
Registry id: NCT01030783

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.